Top

BMC Cancer

Published in:

Open Access 01-12-2024 | Breast Cancer | Research

Unveiling promising breast cancer biomarkers: an integrative approach combining bioinformatics analysis and experimental verification

Authors: Ali Golestan, Ahmad Tahmasebi, Nafiseh Maghsoodi, Seyed Nooreddin Faraji, Cambyz Irajie, Amin Ramezani

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Breast cancer remains a significant health challenge worldwide, necessitating the identification of reliable biomarkers for early detection, accurate prognosis, and targeted therapy.

Materials and methods

Breast cancer RNA expression data from the TCGA database were analyzed to identify differentially expressed genes (DEGs). The top 500 up-regulated DEGs were selected for further investigation using random forest analysis to identify important genes. These genes were evaluated based on their potential as diagnostic biomarkers, their overexpression in breast cancer tissues, and their low median expression in normal female tissues. Various validation methods, including online tools and quantitative Real-Time PCR (qRT-PCR), were used to confirm the potential of the identified genes as breast cancer biomarkers.

Results

The study identified four overexpressed genes (CACNG4, PKMYT1, EPYC, and CHRNA6) among 100 genes with higher importance scores. qRT-PCR analysis confirmed the significant upregulation of these genes in breast cancer patients compared to normal samples.

Conclusions

These findings suggest that CACNG4, PKMYT1, EPYC, and CHRNA6 may serve as valuable biomarkers for breast cancer diagnosis, and PKMYT1 may also have prognostic significance. Furthermore, CACNG4, CHRNA6, and PKMYT1 show promise as potential therapeutic targets. These findings have the potential to advance diagnostic methods and therapeutic approaches for breast cancer.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Deng JL, Xu YH, Wang G. Identification of Potential Crucial Genes and Key Pathways in Breast Cancer Using Bioinformatic Analysis. Front Genet. 2019;10:695. https://doi.org/10.3389/fgene.2019.00695.CrossRefPubMedPubMedCentral

Hing JX, Mok CW, Tan PT, et al. Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance. Breast. 2020;52:95–101. https://doi.org/10.1016/j.breast.2020.05.005.CrossRefPubMedPubMedCentral

Li X, Gou J, Li H, et al. Bioinformatic analysis of the expression and prognostic value of chromobox family proteins in human breast cancer. Sci Rep. 2020;10(1):17739. https://doi.org/10.1038/s41598-020-74792-5.CrossRefPubMedPubMedCentral

Qiu N, He Y, Zhang S, et al. Cullin 7 is a predictor of poor prognosis in breast cancer patients and is involved in the proliferation and invasion of breast cancer cells by regulating the cell cycle and microtubule stability. Oncol Rep. 2018;39(2):603–10. https://doi.org/10.3892/or.2017.6106.CrossRefPubMed

Samad A, Haque F, Nain Z, et al. Computational assessment of MCM2 transcriptional expression and identification of the prognostic biomarker for human breast cancer. Heliyon. 2020;6(10):e05087. https://doi.org/10.1016/j.heliyon.2020.e05087.CrossRefPubMedPubMedCentral

Rossing M, Sørensen CS, Ejlertsen B, et al. Whole genome sequencing of breast cancer. Apmis. 2019;127(5):303–15. https://doi.org/10.1111/apm.12920.CrossRefPubMedPubMedCentral

Akrami S, Tahmasebi A, Moghadam A, et al. Integration of mRNA and protein expression data for the identification of potential biomarkers associated with pancreatic ductal adenocarcinoma. Comput Biol Med. 2023;157:106529.CrossRefPubMed

Gao, J., B.A. Aksoy, U. Dogrusoz, et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal, 2013. 6(269): pl1. https://doi.org/10.1126/scisignal.2004088.

10.

Liaw, A. and M. Wiener, Classification and Regression by RandomForest. Forest, 2001. 23

11.

Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556-w560. https://doi.org/10.1093/nar/gkz430.CrossRefPubMedPubMedCentral

12.

Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–8. https://doi.org/10.1038/s41587-020-0546-8.CrossRefPubMedPubMedCentral

13.

Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18–27. https://doi.org/10.1016/j.neo.2022.01.001.CrossRefPubMedPubMedCentral

14.

Safran M, Rosen N, Twik M, et al. The GeneCards Suite. In: Abugessaisa I, Kasukawa T, editors., et al., Practical Guide to Life Science Databases. Singapore: Springer Nature Singapore; 2021. p. 27–56.CrossRef

15.

Jézéquel, P., W. Gouraud, F. Ben Azzouz, et al., bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses. Database (Oxford), 2021. 2021. https://doi.org/10.1093/database/baab007.

16.

Pathan M, Keerthikumar S, Ang CS, et al. FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15(15):2597–601. https://doi.org/10.1002/pmic.201400515.CrossRefPubMed

17.

Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102(43):15545–50. https://doi.org/10.1073/pnas.0506580102.CrossRefPubMedPubMedCentral

18.

Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2018;47(D1):D941–7. https://doi.org/10.1093/nar/gky1015.CrossRefPubMedCentral

19.

Győrffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. GeroScience. 2023. https://doi.org/10.1007/s11357-023-00742-4.CrossRefPubMedPubMedCentral

20.

Tsherniak A, Vazquez F, Montgomery PG, et al. Defining a cancer dependency map. Cell. 2017;170(3):564-576.e16. https://doi.org/10.1016/j.cell.2017.06.010.CrossRefPubMedPubMedCentral

21.

Ramezani A. CtNorm: Real time PCR cycle of threshold (Ct) normalization algorithm. J Microbiol Methods. 2021;187: 106267. https://doi.org/10.1016/j.mimet.2021.106267.CrossRefPubMed

22.

Heywang-Köbrunner SH, Hacker A, Sedlacek S. Advantages and disadvantages of mammography screening. Breast Care (Basel). 2011;6(3):199–207. https://doi.org/10.1159/000329005.CrossRefPubMed

23.

Afzal S, Hassan M, Ullah S, et al. Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications. Front Mol Biosci. 2022;9:783450. https://doi.org/10.3389/fmolb.2022.783450.CrossRefPubMedPubMedCentral

24.

Bissen D, Foss F, Acker-Palmer A. AMPA receptors and their minions: auxiliary proteins in AMPA receptor trafficking. Cell Mol Life Sci. 2019;76(11):2133–69. https://doi.org/10.1007/s00018-019-03068-7.CrossRefPubMedPubMedCentral

25.

Kamran M, Bhattacharya U, Omar M, et al. ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin. NPJ Breast Cancer. 2022;8(1):99. https://doi.org/10.1038/s41523-022-00474-2.CrossRefPubMedPubMedCentral

26.

Tian, T., X. Li, and J. Zhang, mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. Int J Mol Sci. 2019. 20(3). https://doi.org/10.3390/ijms20030755.

27.

Drago JZ, Ferraro E, Abuhadra N, et al. Beyond HER2: Targeting the ErbB receptor family in breast cancer. Cancer Treat Rev. 2022;109:102436. https://doi.org/10.1016/j.ctrv.2022.102436.CrossRefPubMedPubMedCentral

28.

Kanwar, N., R. Nair, D.-Y. Wang, et al., The calcium channel subunit CACNG4 plays a role in breast cancer metastasis. Cancer Res. 2013. 73(8_Supplement): 5116-5116.

29.

Liu Y, Qi J, Dou Z, et al. Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis. Cell Prolif. 2020;53(2):e12741. https://doi.org/10.1111/cpr.12741.CrossRefPubMed

30.

Asquith CRM, Laitinen T, East MP. PKMYT1: a forgotten member of the WEE1 family. Nat Rev Drug Discov. 2020;19(3):157. https://doi.org/10.1038/d41573-019-00202-9.CrossRefPubMed

31.

Zhang Q, Zhao X, Zhang C, et al. Overexpressed PKMYT1 promotes tumor progression and associates with poor survival in esophageal squamous cell carcinoma. Cancer Manag Res. 2019;11:7813–24. https://doi.org/10.2147/cmar.s214243.CrossRefPubMedPubMedCentral

32.

Wang XM, Li QY, Ren LL, et al. Effects of MCRS1 on proliferation, migration, invasion, and epithelial mesenchymal transition of gastric cancer cells by interacting with Pkmyt1 protein kinase. Cell Signal. 2019;59:171–81. https://doi.org/10.1016/j.cellsig.2019.04.002.CrossRefPubMed

33.

Zhang QY, Chen XQ, Liu XC, et al. PKMYT1 Promotes Gastric Cancer Cell Proliferation and Apoptosis Resistance. Onco Targets Ther. 2020;13:7747–57. https://doi.org/10.2147/ott.s255746.CrossRefPubMedPubMedCentral

34.

Sun, Q.S., M. Luo, H.M. Zhao, et al., Overexpression of PKMYT1 indicates the poor prognosis and enhances proliferation and tumorigenesis in non-small cell lung cancer via activation of Notch signal pathway. Eur Rev Med Pharmacol Sci. 2019. 23(10): 4210-4219. https://doi.org/10.26355/eurrev_201905_17925.

35.

Long HP, Liu JQ, Yu YY, et al. PKMYT1 as a Potential Target to Improve the Radiosensitivity of Lung Adenocarcinoma. Front Genet. 2020;11:376. https://doi.org/10.3389/fgene.2020.00376.CrossRefPubMedPubMedCentral

36.

Deng L, Wang D, Chen S, et al. Epiphycan predicts poor outcomes and promotes metastasis in ovarian cancer. Front Oncol. 2021;11:653782. https://doi.org/10.3389/fonc.2021.653782.CrossRefPubMedPubMedCentral

37.

Hanada Y, Nakamura Y, Ishida Y, et al. Epiphycan is specifically expressed in cochlear supporting cells and is necessary for normal hearing. Biochem Biophys Res Commun. 2017;492(3):379–85. https://doi.org/10.1016/j.bbrc.2017.08.092.CrossRefPubMed

38.

Sun, X., M. Wang, M. Wang, et al., Exploring the Metabolic Vulnerabilities of Epithelial–Mesenchymal Transition in Breast Cancer. Frontiers in Cell and Developmental Biology, 2020. 8. https://doi.org/10.3389/fcell.2020.00655.

39.

Nallanthighal, S., J.P. Heiserman, and D.J. Cheon, Collagen Type XI Alpha 1 (COL11A1): a novel biomarker and a key player in cancer. Cancers (Basel), 2021. 13(5). https://doi.org/10.3390/cancers13050935.

40.

Kotepui M, Punsawad C, Chupeerach C, et al. Differential expression of matrix metalloproteinase-13 in association with invasion of breast cancer. Contemp Oncol (Pozn). 2016;20(3):225–8. https://doi.org/10.5114/wo.2016.61565.CrossRefPubMed

41.

Kotepui M, Punsawad C, Chupeerach C, et al. Differential expression of matrix metalloproteinase-13 in association with invasion of breast cancer. Contemp Oncol/Współczesna Onkologia. 2016;20(3):225–8. https://doi.org/10.5114/wo.2016.61565.CrossRefPubMed

42.

Shi S, Xu C, Fang X, et al. Expression profile of Toll-like receptors in human breast cancer. Mol Med Rep. 2020;21(2):786–94. https://doi.org/10.3892/mmr.2019.10853.CrossRefPubMed

43.

Sun X, Fu X, Xu S, et al. OLR1 is a prognostic factor and correlated with immune infiltration in breast cancer. Int Immunopharmacol. 2021;101(Pt B):108275. https://doi.org/10.1016/j.intimp.2021.108275.CrossRefPubMed

Title: Unveiling promising breast cancer biomarkers: an integrative approach combining bioinformatics analysis and experimental verification
Authors: Ali Golestan
Ahmad Tahmasebi
Nafiseh Maghsoodi
Seyed Nooreddin Faraji
Cambyz Irajie
Amin Ramezani
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Biomarkers
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-11913-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Retraction Note: Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells

Comment on “A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer”

Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects

Effect of young age (below 40 years) on oncologic outcomes in Lebanese patients with breast cancer: a matched cohort study

Health care seeking behaviour towards cervical cancer screening among women aged 30–49 years in Arbaminch town, Southern Ethiopia, 2023

Blue light irradiation inhibits the M2 polarization of the cancer-associated macrophages in colon cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer